Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Effectiveness
Méthylation
CARCINOGENESIS
Small molecules
Stricture
Drug
Rituximab
Disease progression
Venous thromboembolism
Résistance
Colon
Ulcerative colitis
Helicobacter pylori
Thérapie ciblée
Gènes
18 FDG-PET/CT
Colonic epithelial primary cells
PCR
Colorectal cancer Colibactin and lipids
Inflammatory Bowel Diseases
Microbiota
DNA METHYLATION
Gene methylation
Resistance
MICROBIOTA
Original Article Clinical
Epigénétiques
Gene expression
Disability
RISK
Cost effectiveness
Endoscopic treatment
Inclusion
Alkylating agents
IL23
Consensus
HIV
Crohn's disease
Eligibility
Cell adhesion
COLON-CANCER
Biologics
Colectomy
Rituximab plus chlorambucil
Upper gastrointestinal tract
T1118 translocation
IL12
Therapeutics
Bacteria
Monitoring
Fecal microbiota
Clinical guidelines
Genes
Vedolizumab
Ustekinumab
Safety
MALT
Intestinal crypts
Biomarker
Tuberculosis
Surgery
Dysbiose
Acceptability
Kidney diseases
Screening
MARKER
Dysbiosis
Bactéries
Anti-TNF
Over 80s
Immunosuppressant
Clinical trial
Eradication
Algorithm
Methylation
IBD
Tailored therapy
Crohn’s disease
Neoadjuvant chemotherapy
Anti-TNF agents
Heart disease risk factors
Contraindication
DNA methylation
Immune cells
Colorectal cancer
Disease Progression
Maintenance therapy
Inhibitor
Epigenetics
Cancer
Inflammatory bowel disease
Survival
Patients experience
MORTALITY
Parvimonas micra
Colon cancer
Inflammatory bowel diseases
Patient-reported outcome
Primary sclerosing cholangitis
Microbiote
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|